Security Snapshot

CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) Institutional Ownership

CUSIP: G1933S101

13F Institutional Holders and Ownership History from Q4 2022 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

16

Shares (Excl. Options)

1,251,879

Price

$0.85

Type / Class
Equity / Ordinary Shares
Symbol
CASIF on OTC
Shares outstanding
35,821,764
Price per share
$0.21
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,251,879
Total reported value
$1,063,851
% of total 13F portfolios
0%
Share change
-1,354,964
Value change
-$2,036,507
Number of holders
16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares is tracked under CUSIP G1933S101.
  • 16 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 21 to 16 between Q3 2025 and Q4 2025.
  • Reported value moved from $4,327,257 to $1,063,851.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP G1933S101?
CUSIP G1933S101 identifies CASIF - CASI Pharmaceuticals, Inc. - Ordinary Shares in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
He Wei-Wu 53% +17% $4,556,528 +$1,204,800 18,985,535 +36% WEI-WU HE, Ph.D. 23 Mar 2026
Panacea Innovation Ltd 22% +13% $4,698,042 +$999,856 4,651,527 +27% James Huang 16 Dec 2025
Chen Zhenfeng M 11% $4,150,370 2,255,636 Chen Zhenfeng 30 Sep 2025
Huang James 14% $3,177,509 2,161,571 James Huang 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 9.2% $2,066,749 1,987,259 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2025
SPARKLE BYTE LTD 5% $775,088 1,019,852 SPARKLE BYTE LTD 30 Sep 2025
Ho Chi Sing 4.8% -27% $754,405 992,638 0% Zhou Quan 30 Sep 2025

As of 31 Dec 2025, 16 institutional investors reported holding 1,251,879 shares of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF). This represents 3.5% of the company’s total 35,821,764 outstanding shares.

Institutional Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASIF) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,251,879 $1,063,851 -$2,036,507 $0.85 16
2025 Q3 2,606,843 $4,327,257 +$649,422 $1.66 21
2025 Q2 2,245,168 $2,648,852 -$589,075 $1.18 23
2025 Q1 2,744,278 $5,927,688 +$186,001 $2.16 22
2024 Q4 2,658,168 $7,523,090 -$53,802 $2.83 22
2024 Q3 1,322,529 $8,138,853 +$5,984,886 $6.16 20
2024 Q2 352,170 $1,936,256 +$552,357 $5.50 23
2024 Q1 252,002 $909,576 -$261,433 $3.61 20
2023 Q4 275,894 $1,981,066 -$338,820 $7.16 17
2023 Q3 344,608 $882,628 -$268,771 $2.56 18
2023 Q2 449,838 $1,124,376 -$1,180,810 $2.50 18
2023 Q1 929,752 $2,152,582 +$2,152,350 $2.32 19
2022 Q4 100 $179 +$179 $1.79 1

Sponsored